Corcept Therapeutics Incorporated (CORT)
| Previous close | 45.86 |
| Open | 46.13 |
| Bid | 45.41 x 200 |
| Ask | 45.79 x 200 |
| Day's range | 44.74 - 46.39 |
| 52-week range | 20.84 - 47.71 |
| Volume | |
| Avg. volume | 851,723 |
| Market cap | 4.756B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 40.28 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2024. Financial Results Revenue of $163.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue
- GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a
- GlobeNewswire
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84th Scientific Sessions at a featured plenary session titled: “Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes” With 1,055 patients enrolled, CATALYST is the largest and most rigorous study ever conducted to assess the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetesResults demonstrate a hypercortisolism prevalence rate of 24 percent in this p
